Community Health Systems Inc
CYH NYSE Services-General Medical & Surgical Hospitals, Nec Financials FY2016βFY2025
What Community Health Systems Inc does
No business description yet.
- Legal name
- COMMUNITY HEALTH SYSTEMS INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 19, 2026
- Accession Β· CIK
- 0001193125-26-059509
0001108109
Revenue and margins
Community Health Systems Inc had $12.5B of revenue in fiscal 2025, down 1.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $208M in fiscal 2025, 1.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Community Health Systems Inc returned β to shareholders in fiscal 2025. The diluted share count rose 2.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Community Health Systems Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $507M | $118M | $38.0M | $37.0M | $260M |
| Debt incl. finance leases | $12.4B | $11.9B | $11.7B | $11.6B | $10.6B |
| Net debt / EBITDA | 6.1x | 8.7x | 8.0x | 11.3x | 5.4x |
| Current ratio | 1.5x | 1.4x | 1.5x | 1.4x | 1.5x |
| Quick ratio | 1.5x | 1.4x | 1.5x | 1.4x | 1.5x |
| Total assets | $15.2B | $14.7B | $14.5B | $14.1B | $13.2B |
| Total liabilities | $16.0B | $15.4B | $15.3B | $15.4B | $14.0B |
| Shareholders' equity | β$1.4B | β$1.4B | β$1.4B | β$1.9B | β$1.4B |
| Net debt (β = net cash) | $11.9B | $11.7B | $11.7B | $11.6B | $10.3B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 9 | 5 / 9 | 5 / 9 | 6 / 9 | 3 / 9 | 7 / 9 | 5 / 9 | 4 / 9 | 8 / 9 |
| Accruals ratio | β13.0% | β16.4% | β6.4% | β6.7% | β10.5% | 2.3% | β1.7% | β2.4% | β7.0% | β0.2% |
| Altman Z'' | 0.31 | β0.64 | β0.26 | β0.25 | 0.31 | 0.27 | β0.08 | 0.03 | β0.37 | 0.28 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $18.4B | $15.4B | $14.2B | $13.2B | $11.8B | $12.4B | $12.2B | $12.5B | $12.6B | $12.5B |
| Gross profit | $15.4B | $12.7B | $11.8B | $11.1B | $9.8B | $10.3B | $10.2B | $10.5B | $10.7B | $10.6B |
| Operating income | β$860M | β$1.9B | $208M | $650M | $1.1B | $1.4B | $821M | $957M | $542M | $1.5B |
| Pretax income | β$1.7B | β$2.8B | β$715M | β$430M | $422M | $499M | $349M | $207M | β$283M | $724M |
| Income tax | β$104M | β$449M | β$11.0M | $160M | β$185M | $131M | $170M | $191M | $79.0M | $48.0M |
| Net income | β$1.7B | β$2.5B | β$788M | β$675M | $511M | $230M | $46.0M | β$133M | β$516M | $509M |
| Diluted EPS | β$15.54 | β$22.00 | β$6.99 | β$5.93 | $4.39 | $1.76 | $0.35 | β$1.02 | β$3.90 | $3.77 |
| Diluted shares | 0.11B | 0.11B | 0.11B | 0.11B | 0.12B | 0.13B | 0.13B | 0.13B | 0.13B | 0.14B |
| Cash flow | ||||||||||
| Cash from operations | $1.1B | $773M | $274M | $385M | $2.2B | β$131M | $300M | $210M | $480M | $543M |
| Capital expenditure | $744M | $564M | $527M | $438M | $440M | $469M | $415M | $467M | $360M | $335M |
| Free cash flow | $393M | $209M | β$253M | β$53.0M | $1.7B | β$600M | β$115M | β$257M | $120M | $208M |
| Depreciation and amortization | $1.1B | $861M | $700M | $608M | $558M | $540M | $534M | $505M | $486M | $426M |
| Stock-based compensation | $46.0M | $24.0M | $13.0M | $10.0M | $13.0M | $25.0M | $20.0M | $22.0M | $17.0M | $11.0M |
| Acquisitions | $123M | $6.0M | $26.0M | $13.0M | $1.0M | $3.0M | $9.0M | $38.0M | $25.0M | $1.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $238M | $563M | $196M | $216M | $1.7B | $507M | $118M | $38.0M | $37.0M | $260M |
| Total debt | $15.2B | $13.9B | $13.6B | $13.4B | $12.2B | $12.1B | $11.6B | $11.5B | $11.5B | $10.4B |
| Finance lease liabilities | β | β | β | $113M | $79.0M | $241M | $223M | $216M | $195M | $203M |
| Current assets | $4.7B | $4.1B | $3.5B | $3.4B | $4.5B | $3.5B | $3.1B | $3.2B | $3.3B | $3.2B |
| Current liabilities | $2.9B | $2.4B | $2.4B | $2.3B | $2.8B | $2.4B | $2.2B | $2.1B | $2.3B | $2.2B |
| Property and equipment, net | $8.1B | $7.1B | $6.1B | $5.6B | $5.3B | $5.6B | $5.4B | $5.2B | $4.8B | $4.5B |
| Goodwill | $6.5B | $4.7B | $4.6B | $4.3B | $4.2B | $4.2B | $4.2B | $4.0B | $3.8B | $3.3B |
| Intangible assets | $14.0M | $10.0M | β | β | β | β | $2.0M | $20.0M | $15.0M | $7.0M |
| Total assets | $21.9B | $17.5B | $15.9B | $15.6B | $16.0B | $15.2B | $14.7B | $14.5B | $14.1B | $13.2B |
| Total liabilities | $19.7B | $17.6B | $16.8B | $17.2B | $17.1B | $16.0B | $15.4B | $15.3B | $15.4B | $14.0B |
| Shareholders' equity | $1.6B | β$767M | β$1.5B | β$2.2B | β$1.6B | β$1.4B | β$1.4B | β$1.4B | β$1.9B | β$1.4B |
| Margins | ||||||||||
| Gross margin | 83.7% | 82.6% | 83.4% | 83.7% | 83.3% | 83.5% | 83.8% | 84.0% | 84.6% | 85.1% |
| Operating margin | β4.7% | β12.2% | 1.5% | 4.9% | 9.6% | 11.3% | 6.7% | 7.7% | 4.3% | 11.9% |
| EBITDA margin | 1.3% | β6.6% | 6.4% | 9.5% | 14.3% | 15.7% | 11.1% | 11.7% | 8.1% | 15.3% |
| Net margin | β9.3% | β16.0% | β5.6% | β5.1% | 4.3% | 1.9% | 0.4% | β1.1% | β4.1% | 4.1% |
| FCF margin | 2.1% | 1.4% | β1.8% | β0.4% | 14.7% | β4.9% | β0.9% | β2.1% | 0.9% | 1.7% |
| Returns | ||||||||||
| Return on capital | β4.1% | β11.8% | 1.4% | 4.7% | 12.6% | 10.1% | 5.3% | 6.2% | 4.5% | 15.9% |
| Return on capital employed | β4.5% | β12.4% | 1.5% | 4.9% | 8.5% | 10.9% | 6.6% | 7.8% | 4.6% | 13.5% |
| Return on equity | β106.6% | β580.0% | β | β | β | β | β | β | β | β |
| Return on assets | β7.8% | β12.5% | β4.7% | β4.3% | 3.2% | 1.5% | 0.3% | β0.9% | β3.6% | 3.7% |
| Growth | ||||||||||
| Revenue growth | β | β16.7% | β7.8% | β6.7% | β10.8% | 4.9% | β1.3% | 2.3% | 1.2% | β1.2% |
| Net income growth | β | β | β | β | β | β55.0% | β80.0% | β389.1% | β | β |
| EPS growth | β | β | β | β | β | β59.9% | β80.1% | β391.4% | β | β |
| FCF growth | β | β46.8% | β221.1% | β | β | β134.5% | β | β | β | 73.3% |
| Share count change | β | 0.9% | 0.9% | 0.9% | 2.5% | 12.1% | β0.4% | 0.3% | 1.3% | 2.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | 62.5x | β | 14.8x | 10.6x | 6.3x | 6.1x | 8.7x | 8.0x | 11.3x | 5.4x |
| Debt / equity | 9.4x | β | β | β | β | β | β | β | β | β |
| Current ratio | 1.6x | 1.7x | 1.5x | 1.5x | 1.6x | 1.5x | 1.4x | 1.5x | 1.4x | 1.5x |
| Quick ratio | 1.6x | 1.7x | 1.5x | 1.5x | 1.6x | 1.5x | 1.4x | 1.5x | 1.4x | 1.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.0% | 3.7% | 3.7% | 3.3% | 3.7% | 3.8% | 3.4% | 3.7% | 2.8% | 2.7% |
| Stock comp / revenue | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 5.0 | 5.0 | 6.0 | 3.0 | 7.0 | 5.0 | 4.0 | 8.0 |
| Altman Z'' | 0.3 | β0.6 | β0.3 | β0.3 | 0.3 | 0.3 | β0.1 | 0.0 | β0.4 | 0.3 |
| Accruals ratio | β13.0% | β16.4% | β6.4% | β6.7% | β10.5% | 2.3% | β1.7% | β2.4% | β7.0% | β0.2% |
Source: SEC EDGAR XBRL filings (CIK 0001108109). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.